QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Estimating Patient Exposure in Pharmacovigilance

Test your understanding of the concepts covered by Estimating Patient Exposure in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A regulator reviewing an exposure estimate is most likely to focus on which combination of qualities?

Mathematical precision without regard to data limitations Scientific credibility, appropriate metric selection, justified assumptions and methodological transparency The use of the most complex available statistical model Whether the estimate exactly equals the number of patients treated worldwide

Question 2 of 10 For evaluation of immediate hypersensitivity after a vaccine, which exposure measure is generally most directly relevant?

Number of administered vaccine doses Number of patient-years since the vaccination programme began Number of doses manufactured worldwide Number of vaccinated countries

Question 3 of 10 What is the primary reason for independent quality review of exposure calculations?

To ensure that only the highest exposure estimate is selected To assess not only arithmetic accuracy but also data completeness, assumptions, units, reproducibility and unexpected trends To eliminate all uncertainty from post-marketing data To replace the scientific rationale with a standard spreadsheet

Question 4 of 10 Which statement correctly describes the WHO Defined Daily Dose?

It is the legally recommended dose for every individual patient It is the actual dose received by each patient It is an assumed average maintenance dose per day for the principal adult indication It is a substitute for product-specific dosing information in all circumstances

Question 5 of 10 Why does an exposure estimate not by itself establish a spontaneous reporting incidence rate?

Because exposure estimates are always based on clinical trial data Because spontaneous reports may be incomplete, stimulated, influenced by reporting behaviour and not equivalent to all events occurring in exposed patients Because denominators are never useful in pharmacovigilance Because all reported cases are necessarily duplicates

Question 6 of 10 Why may paediatric exposure estimates based solely on wholesale sales be unreliable?

Children always receive adult doses Age- and weight-dependent dosing, formulation changes and specialist supply channels may decouple product quantity from patient numbers Paediatric medicines are never dispensed through hospitals Sales data automatically identify each exposed child

Question 7 of 10 What is the main limitation of using a prescription as evidence of patient exposure?

A prescription necessarily proves that the medicine was administered A prescription may not indicate that treatment was initiated or completed Prescriptions cannot contain dosage information Prescription data are always more representative than worldwide sales

Question 8 of 10 A worldwide PBRER requires a broad estimate of utilisation across many countries, but patient-level data are unavailable globally. Which approach is generally most practical?

Use sales-derived exposure with documented and scientifically justified conversion assumptions Use only data from the country with the largest number of reports Assume that every unit shipped corresponds to one patient Exclude exposure estimation because patient-level data are unavailable

Question 9 of 10 A product is distributed in large quantities during a vaccination campaign, but administration is delayed because of stockpiling. Which exposure measure should be preferred for immediate reaction analysis?

Doses distributed, without qualification Doses administered, because they represent actual administration opportunities Doses manufactured, because manufacturing is more complete Patient-years based on the campaign duration

Question 10 of 10 Why should patient-years based on average daily use be interpreted cautiously for an as-needed medicine?

As-needed medicines are always administered only once Individual use may range from occasional doses to prolonged frequent use, making average duration assumptions uncertain Patient-years cannot be used for any oral medicine As-needed use guarantees that sales equal administration

Knowledge Assessment: Estimating Patient Exposure in Pharmacovigilance

Cookie Settings